Disease Background, Patient Characteristics, and Treatment of Extensive-Stage Small Cell Lung Cancer

Jun 07, 2021 12:00pm -
Jun 07, 2021 01:00pm
Virtual

Event Description

Disease Background, Patient Characteristics, and Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Summary: Each year, the VA manages more than 7,700 patients with newly diagnosed lung cancer.  Small Cell Lung Cancer accounts for about 13% of all patients with lung cancer but is characterized by more aggressive disease and a higher mortality rate than NSCLC.  Most SCLC patients are diagnosed in the metastatic stage, described as ES-SCLC.  For more than 30 years, the standard treatment has been combination platinum chemotherapy.  Recently, the approval of checkpoint inhibitors for the first-line treatment of ES-SCLC has improved survival for ES-SCLC patients. In this talk, we will describe the results of the Phase 3 CASPIAN study evaluating the use of durvalumab and chemotherapy in ES-SCLC.

Target Audience: Primary Care, Pulmonologists, Oncologists, Pharmacists and other Healthcare professional who care for patients with ES-SCLC

Speaker: Brian Pering, Medical Oncologist from Mitchell Cancer Institute
DateMonday June 7, 2021
Time: 12:00 PM ET
Virtual Platform: Go To Webinar
Fee: $0
CME/CE: 0 hrs

 

This webinar is sponsored by:

astrazeneca logo | One Brave Idea

 

 


Event Type:Webinar
Category:Webinar
Early registration ends on May 11, 2021.
Regular registration starts on May 12, 2021 and ends on Jun 06, 2021.
Late registration starts on Jun 07, 2021.